Randomised, double-blind, placebo-controlled phase IIIb study investigating changes in immunological parameters and cutaneous reactivity induced by a short course immunotherapy with ALK grass tablets [Grazax]

Trial Profile

Randomised, double-blind, placebo-controlled phase IIIb study investigating changes in immunological parameters and cutaneous reactivity induced by a short course immunotherapy with ALK grass tablets [Grazax]

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2008

At a glance

  • Drugs Timothy grass pollen allergen extract (Grastek) (Primary)
  • Indications Allergic rhinitis; Grass pollen hypersensitivity
  • Focus Therapeutic Use
  • Sponsors ALK-Abello
  • Most Recent Events

    • 04 Mar 2008 Status changed from in progress to completed.
    • 24 Jul 2007 Status changed from initiated to in progress.
    • 09 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top